Scholars Central

Research articlePublished 15 May 2017

Comparative survival and safety analysis of cisplatin based regimens in gall bladder cancer patients: A retrospective cohort study

Authors: Krishna Murti, Vysakh Chandran, Arun Kumar, Vibha Ghalot, Manoj Kumar Rastogi, Biplab Pal, Krishna Pandey, Pradeep Das

Biomedical Research

Volume 28 · Issue 9 · Pages 4171–4176

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Aim: This is a retrospective cohort study of patients who were treated with different regimens of adjuvant chemotherapy after cholecystectomy due to Gall Bladder Cancer (GBC). Patients and Methods: Data of GBC Patients registered between January 2011 to January 2015 at Mahavir Cancer Sansthan treated with 5-FU plus Cisplatin and Gemcitabine plus Cisplatin as adjuvant chemotherapy were reviewed retrospectively. Eighty patients were enrolled and data was analysed for overall survival and progression free survival. Causality, preventability and severity of Adverse Drug Reactions (ADRs) were also evaluated. Results: Forty patients were assigned with 5FU-Cis and Gem-Cis each. 5FU-Cis gave more ADRs than Gem-Cis. Incidence of ADRs in 5FU-Cis regimen was 62.5% and that of Gem-Cis was 40%. According Modified Hartwig and Siegel scale, “80%” of ADRs shown by 5FU-Cis were moderately severe. Based on Modified Schumock & Thornton Preventability scale, 5FU-Cis and Gem-Cis showed “90%” and “80%” Not Preventable ADRs respectively. As per WHO-UMC Causality assessment scale, “80%” were certain with 5FU-Cis. Gem-Cis showed a mean OS of 11.2 months (95% CI, 10.6-11.8) and mean PFS of 7.4 months (95% CI, 7.3-8.4). 5FU-Cis had a mean OS of 8.1 months (95% CI, 7.7-8.4) and mean PFS of 3.4 months (95% CI, 3.8-4.1). Conclusion: Direct comparison of 5FU-Cis and Gem-Cis showed the latter regimen was superior in OS and PFS. Further prospective studies which define the efficacy and toxicity of these regimens are recommended.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Biomedical Research.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalBiomedical Research
  • SubjectPathology & Lab Medicine
  • BylineArticles whose byline prints “Krishna Murti”
  • BylineArticles whose byline prints “Vysakh Chandran”
  • BylineArticles whose byline prints “Arun Kumar”
  • BylineArticles whose byline prints “Vibha Ghalot”
  • BylineArticles whose byline prints “Manoj Kumar Rastogi”
  • BylineArticles whose byline prints “Biplab Pal”
  • BylineArticles whose byline prints “Krishna Pandey”
  • BylineArticles whose byline prints “Pradeep Das”